Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bone Biologics CorpBBLG · Entity 8560 | Director | January 01, 2019 | April 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bone Biologics Corp
Report date January 01, 2019 · Filed April 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2029-01-01 | Direct | 67,054 |
Reported balance
After 2019-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-01 · Grant · Acquired 54,909 · Balance 67,054 F1: Vests in four (4) successive equal quarterly installments over the one year period measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in four (4) successive equal quarterly installments over the one year period measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2019 Filed Apr 23, 2019 16:05 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 54,909 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001493152-19-005760 · ownership.xml · derivative · entry 1 Booth John J · CIK 0001655227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,054 Underlying: Common Stock · 54,909 shares Expires 2029-01-01 F1 · derivative.exercise_date: Vests in four (4) successive equal quarterly installments over the one year period measured from the date of grant. Read SEC document |
| January 01, 2018 Filed Mar 20, 2018 20:09 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 26,109 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001493152-18-003650 · form4.xml · derivative · entry 1 Booth John J · CIK 0001655227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,442 Underlying: Common Stock · 26,109 shares Expires 2028-01-01 F1 · derivative.exercise_date: Vests in four (4) successive equal quarterly installments over the one year period measured from the date of grant. Read SEC document |
| January 01, 2017 Filed Apr 25, 2017 18:43 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 26,780 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001493152-17-004362 · form4.xml · derivative · entry 1 Booth John J · CIK 0001655227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,333 Underlying: Common Stock · 26,780 shares Expires 2027-01-01 F1 · derivative.exercise_date: Vests in four (4) successive equal quarterly installments over the one-year period measured from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.